A non-genetic engineering platform for rapidly generating and expanding cancer-specific armed T cells

Yi Jou Chen, Michael Chen, Tian Lu Cheng, Yi Shan Tsai, Chang Hung Wang, Che Yi Chen, Tung Yun Wu, Shey Cherng Tzou, Kai Hung Wang, Jing Jy Cheng, An Pei Kao, Shyr Yi Lin*, Kuo Hsiang Chuang*


研究成果: Article同行評審

1 引文 斯高帕斯(Scopus)


Background: Cancer-specific adoptive T cell therapy has achieved successful milestones in multiple clinical treatments. However, the commercial production of cancer-specific T cells is often hampered by laborious cell culture procedures, the concern of retrovirus-based gene transfection, or insufficient T cell purity. Methods: In this study, we developed a non-genetic engineering technology for rapidly manufacturing a large amount of cancer-specific T cells by utilizing a unique anti-cancer/anti-CD3 bispecific antibody (BsAb) to directly culture human peripheral blood mononuclear cells (PBMCs). The anti-CD3 moiety of the BsAb bound to the T cell surface and stimulated the differentiation and proliferation of T cells in PBMCs. The anti-cancer moiety of the BsAb provided these BsAb-armed T cells with the cancer-targeting ability, which transformed the naïve T cells into cancer-specific BsAb-armed T cells. Results: With this technology, a large amount of cancer-specific BsAb-armed T cells can be rapidly generated with a purity of over 90% in 7 days. These BsAb-armed T cells efficiently accumulated at the tumor site both in vitro and in vivo. Cytotoxins (perforin and granzyme) and cytokines (TNF-α and IFN-γ) were dramatically released from the BsAb-armed T cells after engaging cancer cells, resulting in a remarkable anti-cancer efficacy. Notably, the BsAb-armed T cells did not cause obvious cytokine release syndrome or tissue toxicity in SCID mice bearing human tumors. Conclusions: Collectively, the BsAb-armed T cell technology represents a simple, time-saving, and highly safe method to generate highly pure cancer-specific effector T cells, thereby providing an affordable T cell immunotherapy to patients.

期刊Journal of Biomedical Science
出版狀態Published - 12月 2023


深入研究「A non-genetic engineering platform for rapidly generating and expanding cancer-specific armed T cells」主題。共同形成了獨特的指紋。